Abstract
The authors conducted a randomized, double-blind, placebo-controlled, twofold crossover study in 16 patients with MS who presented with severe spasticity to investigate safety, tolerability, and efficacy of oral Delta(9)-Tetrahydrocannabinol (THC) and Cannabis sativa plant extract. Both drugs were safe, but adverse events were more common with plant-extract treatment. Compared with placebo, neither THC nor plant-extract treatment reduced spasticity. Both THC and plant-extract treatment worsened the participant's global impression.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Cannabinoids / administration & dosage*
-
Cannabinoids / adverse effects
-
Cannabis
-
Cross-Over Studies
-
Double-Blind Method
-
Dronabinol / administration & dosage
-
Health Status
-
Humans
-
Middle Aged
-
Multiple Sclerosis / complications
-
Multiple Sclerosis / drug therapy*
-
Muscle Spasticity / drug therapy
-
Muscle Spasticity / etiology
-
Muscle Tonus / drug effects
-
Pain Measurement
-
Plant Extracts / administration & dosage
-
Sample Size
-
Treatment Outcome
Substances
-
Cannabinoids
-
Plant Extracts
-
Dronabinol